Search

Molecular biologist Christine Mayr, MD, PhD, of Memorial Sloan Kettering’s (MSK) Sloan Kettering Institute (SKI) is one of 12 2016 recipients of the prestigious National Institutes of Health (NIH) Director’s Pioneer Award. Established in 2004, the annual award recognizes and supports individual scientists of exceptional creativity who propose pioneering and highly innovative approaches with the potential to produce an unusually high impact on biomedical or behavioral research.

… Tuesday, October 4, 2016 Molecular biologist Christine Mayr, MD, PhD , of Memorial Sloan Kettering’s (MSK) Sloan Kettering Institute (SKI) is one of 12 2016 recipients of the prestigious National Institutes of Health (NIH) Director’s Pioneer Award. Established in 2004, the annual award recognizes and

New MSK research investigates whether introducing new mutations could make immunotherapy more effective against some cancers; shows that people in their 90s who underwent lung cancer surgery had positive outcomes; shares lessons on the responsible governance of artificial intelligence in oncology; studies AI-assisted biomarker assessment in lung cancer; and demonstrates a cancer-trained large language model has strong predictive value.

… Tuesday, July 15, 2025 New research from Memorial Sloan Kettering Cancer Center (MSK) investigates whether introducing new mutations could make immunotherapy more effective against some cancers; shows that people in their 90s who underwent lung cancer surgery had positive outcomes; shares lessons on

Early-onset colorectal cancer (CRC) is likely clinically and genomically indistinguishable from average-onset cancer, according to a recent study published in the Journal of the National Cancer Institute by MSK investigators.

… Monday, September 13, 2021 Early-onset colorectal cancer (CRC) is likely clinically and genomically indistinguishable from average-onset cancer, according to a recent study published in the Journal of the National Cancer Institute by MSK investigators.The findings suggest that aggressive treatment for

Internationally recognized physician-scientist José Baselga has been named Physician-in-Chief of Memorial Hospital. He joins Memorial Sloan Kettering from Massachusetts General Hospital.

… Wednesday, September 5, 2012 Memorial Sloan Kettering Cancer Center announced today that José Baselga has been named Physician-in-Chief of Memorial Hospital . He will begin on January 1, 2013. Currently, Dr. Baselga is Chief of the Division of Hematology/Oncology at Massachusetts General Hospital (MGH

A study reveals unexpected insights into how cells prepare broken DNA strands to be rejoined, preventing mutations that can cause cancer.

… Friday, January 6, 2017 Summary Cells need to repair damaged DNA to prevent mutations that can lead to cancer. Though researchers know that broken DNA strands need to be processed in some way before they are rejoined, how this happens has been a mystery. A new study in yeast shows the early involvement

Learn how eating a plant-based diet may prevent MGUS and smoldering myeloma from developing into multiple myeloma, according to MSK research.

… Monday, December 8, 2025 Multiple myeloma is a cancer that arises from a type of white blood cell called a plasma cell, which is produced in the bone marrow. Multiple myeloma is sometimes preceded by conditions called monoclonal gammopathy of undetermined significance (MGUS) or smoldering myeloma , which

In the largest-ever genetic analysis of people being treated with checkpoint inhibitors, Memorial Sloan Kettering researchers looked at patients who received several checkpoint inhibitors for a number of different cancers at many different hospitals. Researchers found that people who had a greater diversity and more variation in their human leukocyte antigen (HLA) genes responded much better to immunotherapy compared with those who had less diversity. For more information or to speak with an expert, contact Rebecca Williams at [email protected].

… Thursday, December 7, 2017 Bottom line: Patient-specific HLA genotype influences response to immune checkpoint inhibitors . Journal: “Patient HLA genotype influences cancer response to checkpoint blockade immunotherapy” appears in the December 7, 2017, issue of Science . Authors : The senior author was

Discover how turmeric may help fight cancer.

… Wednesday, October 27, 2021 You may have read about the health benefits of turmeric, a spice native to southeast Asia. For more than 5,000 years, people have used it to treat a variety of ailments, such as skin disorders and digestive issues. Research suggests that its active ingredient, curcumin, may

The Marie-Josée Kravis Center for Cancer Immunobiology (CCI), made possible by a generous $40 million gift from Henry R. Kravis to honor the visionary leadership of his wife, Marie-Josée Kravis, will establish a strategic research infrastructure that will seamlessly unite MSK scientists and physicians to further accelerate immunotherapy treatments for people with cancer.

… Monday, May 22, 2023 Memorial Sloan Kettering Cancer Center (MSK) today announced the creation of The Marie-Josée Kravis Center for Cancer Immunobiology (CCI), a hub for immunotherapy research that will elevate, centralize, and prioritize the full spectrum of immuno-oncology research across the institution

Cell therapies that use patients’ own immune cells to attack cancer — including CAR T cell therapy, an approach developed at MSK — are a promising and rapidly growing area of research.

… Tuesday, March 31, 2015 Summary Cell therapies, a promising new type of cancer treatment, aim to boost the immune system by giving immune cells the information they need to better recognize tumor cells as foreign and attack them. These therapies are being used to treat a few types of cancer, with more